Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Sestak

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2019
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC studyRichard Buus, Ivana Sestak, Stephen Barron, et al.
Breast Cancer Research and Treatment|April 29, 2015
Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trialPatricia A Mote, Anne Gompel, Chris Howe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention TrialsJack Cuzick, Adam R Brentnall, Corrinne Segal, et al.
International Journal of Cancer|July 7, 2016
Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCISAliana Guerrieri-Gonzaga, Ivana Sestak, Matteo Lazzeroni, et al.
Lancet (London, England)|December 17, 2013
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
The Lancet. Oncology|September 17, 2013
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationDennis C Sgroi, Ivana Sestak, Jack Cuzick, et al.
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapySalvatore Pece, Ivana Sestak, Francesca Montani, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2019
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC studyRichard Buus, Ivana Sestak, Stephen Barron, et al.
Breast Cancer Research and Treatment|April 29, 2015
Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trialPatricia A Mote, Anne Gompel, Chris Howe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention TrialsJack Cuzick, Adam R Brentnall, Corrinne Segal, et al.
International Journal of Cancer|July 7, 2016
Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCISAliana Guerrieri-Gonzaga, Ivana Sestak, Matteo Lazzeroni, et al.
Lancet (London, England)|December 17, 2013
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
The Lancet. Oncology|September 17, 2013
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationDennis C Sgroi, Ivana Sestak, Jack Cuzick, et al.
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapySalvatore Pece, Ivana Sestak, Francesca Montani, et al.
Pageof 7